1 completed, 1 not yet recruiting, 1 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Not yet recruiting 1 |
Follow Combined Hepatocellular and Cholangiocarcinoma: new trials by email Literature Review of Combined Hepatocellular and Cholangiocarcinoma trials Research Report on Combined Hepatocellular and Cholangiocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma Tremelimumab, Durvalumab, Gemcitabine - Combined Hepatocellular and Cholangiocarcinoma | Phase 2 | Not yet recruiting | Mehmet Akce | 29 | 2026-10-01 | 2026-10-05 |
| Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data Interventional therapies combined with or without systemic drugs - Combined Hepatocellular-cholangiocarcinoma, Combined Hepatocellular Carcinoma and Cholangiocarcinoma | Recruiting | Zhongda Hospital | 198 | 2024-12-31 | 2025-02-27 | |
| Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma derazantinib - Intrahepatic Cholangiocarcinoma, Combined Hepatocellular and Cholangiocarcinoma | Phase 2 | Completed | Basilea Pharmaceutica | 148 | 2017-09-28 | 2023-12-19 |
Liver Neoplasms (3) · Bile Duct Neoplasms (1) · Biliary Tract Neoplasms (1) · Cholangiocarcinoma (1)
Digestive System Diseases (3) · Digestive System Neoplasms (3) · Liver Diseases (3) · Neoplasms (3) · Neoplasms by Site (3) · Adenocarcinoma (1) · Bile Duct Diseases (1) · Biliary Tract Diseases (1) · Carcinoma (1) · Neoplasms by Histologic Type (1) · Neoplasms, Glandular and Epithelial (1)
Cisplatin (1) · Gemcitabine (1) · derazantinib (1) · durvalumab (1) · tremelimumab (1)
Basilea Pharmaceutica (1) · Mehmet Akce (1) · Zhongda Hospital (1)
United States (2) · Belgium (1) · Canada (1) · China (1) · France (1) · Germany (1) · Ireland (1) · Italy (1) · South Korea (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Gao-Jun Teng, M.D (1) · Mehmet Akce, MD (1)